Sam Altman, OpenAI will reportedly back a startup that takes on Musk’s Neuralink

Sam Altman is reportedly co-founding Merge Labs, a new brain-to-computer interface startup seeking funding, potentially from OpenAI's ventures team, at an $850 million valuation. This initiative positions Altman to directly compete with Elon Musk's Neuralink, a BCI firm valued at $9 billion and already conducting human trials, intensifying the rivalry between the two tech leaders in the nascent BCI sector. The venture signals a significant push into advanced human-computer integration, a field with revolutionary potential.

Analysis

Sam Altman is reportedly entering the brain-to-computer interface (BCI) sector by co-founding Merge Labs, a new venture with a prospective valuation of $850 million. The information, currently speculative and unconfirmed by OpenAI, indicates that funding may originate from OpenAI's own ventures team. This development positions Merge Labs as a direct, albeit nascent, competitor to Elon Musk's Neuralink. A significant valuation and development gap exists between the two; Neuralink is a more mature entity valued at $9 billion following a $600 million Series E, and is already in human trials with its implantable device. The emergence of Merge Labs underscores the intensifying personal and professional rivalry between Altman and Musk, potentially accelerating innovation and capital allocation within the high-risk, high-reward BCI market. This move signals a strategic push by major tech figures into the next frontier of human-computer integration, a theme with profound long-term implications for the technology and healthcare sectors.

Key Decisions for Investors

• Investors should increase monitoring of the private brain-to-computer interface (BCI) sector, as the entry of a prominent figure like Sam Altman signals heightened validation and potential for accelerated innovation.
• For those with an interest in Neuralink, the emergence of Merge Labs as a direct competitor warrants a re-evaluation of the competitive landscape, particularly concerning the race for talent and technological milestones.
• Given the speculative nature of the news, immediate action is premature; the priority should be to await official confirmation of Merge Labs' formation and funding, as the composition of the investor syndicate will be a key indicator of its long-term viability.
• Long-term investors should begin to identify potential public companies in the BCI supply chain, such as those in specialized microfabrication or biocompatible materials, that could benefit from the growth of multiple well-funded players in the space.